Pelthos Therapeutics (PTHS) Cash & Equivalents (2022 - 2026)

Pelthos Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $18.0 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 3403.51% year-over-year to $18.0 million; the TTM figure through Dec 2025 stood at $18.0 million (up 3403.51% YoY), while the FY2025 annual figure was $18.0 million, up 3403.51% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $18.0 million, up from $14.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $18.0 million in Q4 2025, with the low at $22786.0 in Q3 2023.
• The 4-year median for Cash & Equivalents is $131317.0 (2025), against an average of $3.1 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 7656.4% in 2024, then tumbled 97.54% in 2025.
• Pelthos Therapeutics' Cash & Equivalents stood at $55074.0 in 2022, then surged by 74.31% to $96000.0 in 2023, then surged by 434.38% to $513000.0 in 2024, then soared by 3403.51% to $18.0 million in 2025.
• Business Quant data shows PTHS's Cash & Equivalents at $18.0 million in Q4 2025, $14.3 million in Q3 2025, and $59172.0 in Q2 2025.